These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 26070500)

  • 21. Differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma on gadoxetic acid-enhanced liver MR imaging.
    Kim R; Lee JM; Shin CI; Lee ES; Yoon JH; Joo I; Kim SH; Hwang I; Han JK; Choi BI
    Eur Radiol; 2016 Jun; 26(6):1808-17. PubMed ID: 26373763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatocellular adenoma and focal nodular hyperplasia: value of gadoxetic acid-enhanced MR imaging in differential diagnosis.
    Grazioli L; Bondioni MP; Haradome H; Motosugi U; Tinti R; Frittoli B; Gambarini S; Donato F; Colagrande S
    Radiology; 2012 Feb; 262(2):520-9. PubMed ID: 22282184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Validation of diagnostic criteria using gadoxetic acid-enhanced and diffusion-weighted MR imaging for small hepatocellular carcinoma (<= 2.0 cm) in patients with hepatitis-induced liver cirrhosis.
    Park MJ; Kim YK; Lee MH; Lee JH
    Acta Radiol; 2013 Mar; 54(2):127-36. PubMed ID: 23148300
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imaging features of subcentimeter hypointense nodules on gadoxetic acid-enhanced hepatobiliary phase MR imaging that progress to hypervascular hepatocellular carcinoma in patients with chronic liver disease.
    Jang KM; Kim SH; Kim YK; Choi D
    Acta Radiol; 2015 May; 56(5):526-35. PubMed ID: 24838304
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of gadoxetic acid-enhanced magnetic resonance imaging and contrast-enhanced computed tomography with histopathological examinations for the identification of hepatocellular carcinoma: a multicenter phase III study.
    Tsurusaki M; Sofue K; Isoda H; Okada M; Kitajima K; Murakami T
    J Gastroenterol; 2016 Jan; 51(1):71-9. PubMed ID: 26130441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Differential diagnosis of focal liver lesions with MRI using the superparamagnetic contrast medium endorem].
    Vogl TJ; Hammerstingl R; Keck H; Felix R
    Radiologe; 1995 Nov; 35(11 Suppl 2):S258-66. PubMed ID: 8588032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. OATPB1/B3 and MRP3 expression in hepatocellular adenoma predicts Gd-EOB-DTPA uptake and correlates with risk of malignancy.
    Sciarra A; Schmidt S; Pellegrinelli A; Maggioni M; Dondossola D; Pasquier J; Cigala C; Tosi D; Halkic N; Bulfamante G; Viale G; Bosari S; Balabaud C; Bioulac-Sage P; Sempoux C
    Liver Int; 2019 Jan; 39(1):158-167. PubMed ID: 30218633
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative analysis of gadoxetic acid-enhanced MRI for the differential diagnosis of focal liver lesions: Comparison between estimated intralesional gadoxetic acid retention by T1 mapping and conventional processing methods.
    Morisaka H; Seno D; Sakurai Y; Sano K; Akamine Y; Ichikawa T; Okada Y
    Eur J Radiol; 2021 May; 138():109620. PubMed ID: 33713905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic per-patient accuracy of an abbreviated hepatobiliary phase gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance.
    Marks RM; Ryan A; Heba ER; Tang A; Wolfson TJ; Gamst AC; Sirlin CB; Bashir MR
    AJR Am J Roentgenol; 2015 Mar; 204(3):527-35. PubMed ID: 25714281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MR imaging features for improved diagnosis of hepatocellular carcinoma in the non-cirrhotic liver: Multi-center evaluation.
    Fischer MA; Raptis DA; Donati OF; Hunziker R; Schade E; Sotiropoulos GC; McCall J; Bartlett A; Bachellier P; Frilling A; Breitenstein S; Clavien PA; Alkadhi H; Patak MA
    Eur J Radiol; 2015 Oct; 84(10):1879-87. PubMed ID: 26194029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inflammatory hepatocellular adenomas can mimic focal nodular hyperplasia on gadoxetic acid-enhanced MRI.
    Agarwal S; Fuentes-Orrego JM; Arnason T; Misdraji J; Jhaveri KS; Harisinghani M; Hahn PF
    AJR Am J Roentgenol; 2014 Oct; 203(4):W408-14. PubMed ID: 25055198
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Subtraction Images of Gadoxetic Acid-Enhanced MRI: Effect on the Diagnostic Performance for Focal Hepatic Lesions in Patients at Risk for Hepatocellular Carcinoma.
    Choi SH; Kim SY; Lee SS; Shim JH; Byun JH; Baek S; Lee MG
    AJR Am J Roentgenol; 2017 Sep; 209(3):584-591. PubMed ID: 28609188
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of small hepatocellular carcinoma: can gadoxetic acid-enhanced magnetic resonance imaging replace combining gadopentetate dimeglumine-enhanced and superparamagnetic iron oxide-enhanced magnetic resonance imaging?
    Kim YK; Kim CS; Han YM; Park G
    Invest Radiol; 2010 Nov; 45(11):740-6. PubMed ID: 20644488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gadoxetic acid enhanced MRI for differentiation of FNH and HCA: a single centre experience.
    Grieser C; Steffen IG; Kramme IB; Bläker H; Kilic E; Perez Fernandez CM; Seehofer D; Schott E; Hamm B; Denecke T
    Eur Radiol; 2014 Jun; 24(6):1339-48. PubMed ID: 24658870
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypervascular hepatocellular carcinoma 1 cm or smaller in patients with chronic liver disease: characterization with gadoxetic acid-enhanced MRI that includes diffusion-weighted imaging.
    Kim JE; Kim SH; Lee SJ; Rhim H
    AJR Am J Roentgenol; 2011 Jun; 196(6):W758-65. PubMed ID: 21606265
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characteristics and distinguishing features of hepatocellular adenoma and focal nodular hyperplasia on gadoxetate disodium-enhanced MRI.
    Purysko AS; Remer EM; Coppa CP; Obuchowski NA; Schneider E; Veniero JC
    AJR Am J Roentgenol; 2012 Jan; 198(1):115-23. PubMed ID: 22194486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of MRI with hepatospecific contrast agent in the identification and characterization of focal liver lesions: pathological correlation in explanted livers.
    Orlacchio A; Chegai F; Fabiano S; Merolla S; Funel V; Di Giuliano F; Manuelli M; Tisone G; Francioso S; Angelico M; Palmieri G; Simonetti G
    Radiol Med; 2016 Jul; 121(7):588-96. PubMed ID: 27100719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gadoxetic acid-enhanced magnetic resonance imaging can predict the pathologic stage of solitary hepatocellular carcinoma.
    Chou YC; Lao IH; Hsieh PL; Su YY; Mak CW; Sun DP; Sheu MJ; Kuo HT; Chen TJ; Ho CH; Kuo YT
    World J Gastroenterol; 2019 Jun; 25(21):2636-2649. PubMed ID: 31210715
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dynamic enhancement pattern of HCC smaller than 3 cm in diameter on gadoxetic acid-enhanced MRI: comparison with multiphasic MDCT.
    Park VY; Choi JY; Chung YE; Kim H; Park MS; Lim JS; Kim KW; Kim MJ
    Liver Int; 2014 Nov; 34(10):1593-602. PubMed ID: 24673802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Focal lesions in the cirrhotic liver: their pivotal role in gadoxetic acid-enhanced MRI and recognition by the Western guidelines.
    Golfieri R; Garzillo G; Ascanio S; Renzulli M
    Dig Dis; 2014; 32(6):696-704. PubMed ID: 25376286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.